Dr. Phillip Moen of IMDx will present the unique design and development of two viral assays: the CE-marked HSV-1/2 assay and the Influenza A/B and RSV assay which is anticipated to receive CE-marking in early 2013.
These viral assays are part of a group of infectious disease assays designed, developed and manufactured by IMDx under a multi-year distribution agreement with Abbott. In the past year, IMDx has obtained CE-marking and commercialized 4 high-throughput diagnostic tests designed for use on the Abbott m2000™ RealTime System. In addition to the HSV-1/2 assay, this collection of assays includes 3 assays that target threatening bacterial infections: Clostridium difficile, Vancomycin-resistant Enterococci and Group B Streptococcus.
To attend the IMDx presentations at ESCV, please visit:
Wednesday, September 05, 2012, 10:30 – 11:30am, Poster Spot P-106
“Development of an Automated High-Throughput Diagnostic Assay for Herpes Simplex Virus Infection”
Wednesday, September 05, 2012, 6:00pm, Oral Spot O-016
“Development of a Fully Automated Test for Rapid and Sensitive Detection of Influenza A/B and Respiratory Syncytial Viruses”
About IMDx
Based in Cambridge, MA, USA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.
